The foundations of the field of microbial therapies and Finch’s platform date back to the pioneering research of Dr. Thomas Borody, one of our scientific co-founders. Dr. Borody’s work from as early as 1988 demonstrated the promise of engineering the microbiome. Together with our scientific collaborators, Drs. Alexander Khoruts and Michael Sadowsky, this work has led to an innovative, first-in-class, orally-administered microbiota formulation that is currently in clinical development.

Building on the groundbreaking work of our founder and scientific collaborators, Finch’s Full-Spectrum Microbiota platform restores the functional diversity lost after antibiotic exposure or other disruptions to the microbiome. CP101, our lead clinical candidate is currently in a clinical trial, PRISM 3, for patients with recurrent Clostridium difficile infection (rCDI).